Company profile OMER

Omeros Corporation
omeros is a seattle-based biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system.
Quarter analysis & expected interest

There is not enough data for Omeros biopharmaceutical to provide analysis

Correlation between past revenue and Omeros biopharmaceutical search interest

There is not enough data for Omeros biopharmaceutical to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Omeros biopharmaceutical to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: November 06 2023 23:19:15.

After 34 days of this quarter the interest is at 48.0. Based on that we can calculate that during remaining 58 days it will total up to 130.0.
Omeros stock expected interest is significantly higher compared to same quarter last year (+46.1%) but similar to previous quarter.

YearQ1Q2Q3Q4
2018 - - - 96
2019 196
104.2% QoQ
205
4.6% QoQ
200
-2.4% QoQ
184
91.7% YoY -8.0% QoQ
2020 233
18.9% YoY 26.6% QoQ
248
21.0% YoY 6.4% QoQ
397
98.5% YoY 60.1% QoQ
369
100.5% YoY -7.1% QoQ
2021 363
55.8% YoY -1.6% QoQ
267
7.7% YoY -26.4% QoQ
196
-50.6% YoY -26.6% QoQ
281
-23.8% YoY 43.4% QoQ
2022 181
-50.1% YoY -35.6% QoQ
132
-50.6% YoY -27.1% QoQ
125
-36.2% YoY -5.3% QoQ
89
-68.3% YoY -28.8% QoQ
2023 68
-62.4% YoY -23.6% QoQ
137
3.8% YoY 101.5% QoQ
121
-3.2% YoY -11.7% QoQ
48
-46.1% YoY -60.3% QoQ
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Omeros stock search interestLast update: November 06 2023 23:19:15.
Correlation coefficient between keyword and revenue is -0.12
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: November 06 2023 23:19:16.

The average 5 years interest of Omeros stock was 15.91 per week.
The last year interest of Omeros stock compared to the last 5 years has changed by -47.39%.
This is something to be checked.
The last year interest is quite lower compared to 5 years ago. It has decreased by -43.71%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 09 2024 07:28:34.

After 39 days of this quarter the interest is at 85.0. Based on that we can calculate that during remaining 52 days it will total up to 198.0.
Omeros news expected interest is significantly higher compared to previous quarter (+164.0%) and same quarter last year (+117.6%).

YearQ1Q2Q3Q4
201964
321
401.6% QoQ
226
-29.6% QoQ
126
-44.2% QoQ
2020 106
65.6% YoY -15.9% QoQ
82
-74.5% YoY -22.6% QoQ
152
-32.7% YoY 85.4% QoQ
42
-66.7% YoY -72.4% QoQ
2021 90
-15.1% YoY 114.3% QoQ
98
19.5% YoY 8.9% QoQ
117
-23.0% YoY 19.4% QoQ
227
440.5% YoY 94.0% QoQ
2022 24
-73.3% YoY -89.4% QoQ
17
-82.7% YoY -29.2% QoQ
20
-82.9% YoY 17.6% QoQ
100
-55.9% YoY 400.0% QoQ
2023 91
279.2% YoY -9.0% QoQ
26
52.9% YoY -71.4% QoQ
110
450.0% YoY 323.1% QoQ
75
-25.0% YoY -31.8% QoQ
2024 85
-6.6% YoY 13.3% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Omeros news search interestLast update: February 09 2024 07:28:34.
Correlation coefficient between keyword and revenue is 0.35
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 09 2024 07:28:35.

The average 5 years interest of Omeros news was 8.43 per week.
The last year interest of Omeros news compared to the last 5 years has changed by -11.74%.
This is something to be checked.
The last year interest is quite lower compared to 5 years ago. It has decreased by -52.06%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Omeros pipeline to provide analysis

Correlation between past revenue and Omeros pipeline search interest

There is not enough data for Omeros pipeline to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Omeros pipeline to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Omeros clinical trials to provide analysis

Correlation between past revenue and Omeros clinical trials search interest

There is not enough data for Omeros clinical trials to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Omeros clinical trials to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Omeros COVID-19 to provide analysis

Correlation between past revenue and Omeros COVID-19 search interest

There is not enough data for Omeros COVID-19 to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Omeros COVID-19 to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Omeros MASP-2 to provide analysis

Correlation between past revenue and Omeros MASP-2 search interest

There is not enough data for Omeros MASP-2 to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Omeros MASP-2 to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Omeros small-molecule inhibitors to provide analysis

Correlation between past revenue and Omeros small-molecule inhibitors search interest

There is not enough data for Omeros small-molecule inhibitors to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Omeros small-molecule inhibitors to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Omeros protein therapeutics to provide analysis

Correlation between past revenue and Omeros protein therapeutics search interest

There is not enough data for Omeros protein therapeutics to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Omeros protein therapeutics to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for OMER
Earnings date: 2024-02-28 After close
Company name: Omeros Corporation
Sector: Manufacturing
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2026-05-14T10:59:15Z

Analyst Upgrades
HC Wainwright & Co. Reiterates Buy on Omeros, Maintains $40 Price Target

2026-05-13T20:02:00Z

BusinessWire
Omeros Corporation Reports First Quarter 2026 Financial Results

2026-05-11T20:02:00Z

BusinessWire
Omeros Corporation to Announce First Quarter Financial Results on May 13, 2026

2026-04-20T11:00:00Z

GlobeNewswire
Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer

2026-04-16T12:45:00Z

BusinessWire
CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA® (narsoplimab-wuug)

2026-03-31T20:02:00Z

BusinessWire
Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results

2026-03-26T12:45:00Z

BusinessWire
Omeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026

2026-03-21T07:23:00Z

BusinessWire
Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment

2026-02-17T13:45:00Z

BusinessWire
Omeros Announces Successful Primate Study in OncotoX-AML™ Drug Program

2026-01-27T15:54:24Z

Analyst Upgrades
D. Boral Capital Maintains Buy on Omeros, Maintains $36 Price Target

2026-01-08T13:21:37Z

Analyst Upgrades
HC Wainwright & Co. Maintains Buy on Omeros, Raises Price Target to $40

2026-01-08T13:09:03Z

Analyst Upgrades
D. Boral Capital Maintains Buy on Omeros, Maintains $36 Price Target

2025-12-26T23:36:00Z

BusinessWire
Omeros Announces New Date for YARTEMLEA® Approval Conference Call

2025-12-24T16:56:06Z

Analyst Upgrades
D. Boral Capital Maintains Buy on Omeros, Maintains $36 Price Target

2025-12-24T14:00:00Z

BusinessWire
FDA Approves Omeros' YARTEMLEA® – First and Only Therapy Indicated for TA-TMA